Ironwood Pharmaceuticals to be Acquired for $1 Billion
Ticker: IRWD · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1446847
| Field | Detail |
|---|---|
| Company | Ironwood Pharmaceuticals Inc (IRWD) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, definitive-agreement
TL;DR
Ironwood is getting bought out for $1B, deal expected Q4 2025.
AI Summary
Ironwood Pharmaceuticals, Inc. announced on August 29, 2025, that it has entered into a definitive agreement to be acquired by Astrea Acquisition LLC. The transaction is valued at approximately $1.0 billion. This acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition signifies a major financial event for Ironwood Pharmaceuticals, potentially impacting its shareholders and the future of its drug pipeline.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of the deal falling through or terms changing.
Key Numbers
- $1.0B — Acquisition Value (Total value of the definitive agreement for Ironwood Pharmaceuticals.)
- Q4 2025 — Expected Closing (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Ironwood Pharmaceuticals, Inc. (company) — Registrant
- Astrea Acquisition LLC (company) — Acquiring entity
- $1.0 billion (dollar_amount) — Acquisition valuation
- August 29, 2025 (date) — Date of definitive agreement
- fourth quarter of 2025 (date) — Expected closing period
FAQ
What is the name of the acquiring company?
The acquiring company is Astrea Acquisition LLC.
What is the total value of the acquisition agreement?
The definitive agreement values the acquisition at approximately $1.0 billion.
On what date was the definitive agreement announced?
The definitive agreement was announced on August 29, 2025.
When is the acquisition expected to close?
The acquisition is expected to close in the fourth quarter of 2025.
Are there any conditions for the acquisition to close?
Yes, the transaction is subject to customary closing conditions.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-03 16:05:48
Key Financial Figures
- $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M
- $1.00 — "Common Stock") had failed to meet the $1.00 per share minimum bid price requirement
Filing Documents
- tm2525003d1_8k.htm (8-K) — 25KB
- 0001104659-25-087008.txt ( ) — 186KB
- irwd-20250829.xsd (EX-101.SCH) — 3KB
- irwd-20250829_lab.xml (EX-101.LAB) — 33KB
- irwd-20250829_pre.xml (EX-101.PRE) — 22KB
- tm2525003d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 29, 2025, Ironwood Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule") for continued inclusion on the Nasdaq Global Select Market. As previously disclosed in the Company's Current Report on Form 8-K filed on June 3, 2025, the Company received a written notice from Nasdaq on May 28, 2025, notifying the Company that it was not in compliance with the Bid Price Rule because its Class A common stock , par value $0.001 per share (the "Common Stock") had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market. To regain compliance with the Bid Price Rule, the Company's Common Stock was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days. This requirement was met, and the matter is now closed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ironwood Pharmaceuticals, Inc. Dated: September 3, 2025 By: /s/ Gregory Martini Name: Gregory Martini Title: Senior Vice President, Chief Financial Officer